HYDREIGHT TECHNOLOGIES INC (NURS.CA) Fundamental Analysis & Valuation

TSX-V:NURS • CA44877L1013

Current stock price

2.39 CAD
-0.28 (-10.49%)
Last:

This NURS.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. NURS.CA Profitability Analysis

1.1 Basic Checks

  • In the past year NURS was profitable.
  • In the past year NURS had a positive cash flow from operations.
NURS.CA Yearly Net Income VS EBIT VS OCF VS FCFNURS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -2M -4M

1.2 Ratios

  • NURS has a better Return On Assets (2.04%) than 100.00% of its industry peers.
  • NURS's Return On Equity of 4.79% is amongst the best of the industry. NURS outperforms 100.00% of its industry peers.
  • NURS's Return On Invested Capital of 1.46% is amongst the best of the industry. NURS outperforms 90.00% of its industry peers.
Industry RankSector Rank
ROA 2.04%
ROE 4.79%
ROIC 1.46%
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NURS.CA Yearly ROA, ROE, ROICNURS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

  • With an excellent Profit Margin value of 1.85%, NURS belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 1.48%, NURS belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
  • NURS has a Gross Margin (29.16%) which is in line with its industry peers.
  • NURS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 1.48%
PM (TTM) 1.85%
GM 29.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
NURS.CA Yearly Profit, Operating, Gross MarginsNURS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NURS.CA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NURS is destroying value.
  • Compared to 1 year ago, NURS has more shares outstanding
  • NURS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NURS.CA Yearly Shares OutstandingNURS.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
NURS.CA Yearly Total Debt VS Total AssetsNURS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M

2.2 Solvency

  • NURS has an Altman-Z score of 7.47. This indicates that NURS is financially healthy and has little risk of bankruptcy at the moment.
  • NURS's Altman-Z score of 7.47 is fine compared to the rest of the industry. NURS outperforms 70.00% of its industry peers.
  • A Debt/Equity ratio of 0.83 indicates that NURS is somewhat dependend on debt financing.
  • NURS has a Debt to Equity ratio of 0.83. This is in the lower half of the industry: NURS underperforms 60.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF N/A
Altman-Z 7.47
ROIC/WACC0.17
WACC8.61%
NURS.CA Yearly LT Debt VS Equity VS FCFNURS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 -500K -1M -1.5M

2.3 Liquidity

  • NURS has a Current Ratio of 4.47. This indicates that NURS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 4.47, NURS belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
  • A Quick Ratio of 4.47 indicates that NURS has no problem at all paying its short term obligations.
  • NURS has a better Quick ratio (4.47) than 90.00% of its industry peers.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47
NURS.CA Yearly Current Assets VS Current LiabilitesNURS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. NURS.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 128.24% over the past year.
  • The Revenue has grown by 59.17% in the past year. This is a very strong growth!
  • Measured over the past years, NURS shows a very strong growth in Revenue. The Revenue has been growing by 137.35% on average per year.
EPS 1Y (TTM)128.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%426.09%
Revenue 1Y (TTM)59.17%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%132.42%

3.2 Future

  • The Earnings Per Share is expected to grow by 267.38% on average over the next years. This is a very strong growth
  • NURS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 130.31% yearly.
EPS Next Y391.35%
EPS Next 2Y457.98%
EPS Next 3Y267.39%
EPS Next 5YN/A
Revenue Next Year125.3%
Revenue Next 2Y207.15%
Revenue Next 3Y130.32%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
NURS.CA Yearly Revenue VS EstimatesNURS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
NURS.CA Yearly EPS VS EstimatesNURS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0.1 0.2 0.3 0.4

More info and screens

Find the best growth stocksShow best growing peers

6

4. NURS.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 239.00, NURS can be considered very expensive at the moment.
  • 90.00% of the companies in the same industry are more expensive than NURS, based on the Price/Earnings ratio.
  • NURS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.23.
  • A Price/Forward Earnings ratio of 7.89 indicates a rather cheap valuation of NURS.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NURS indicates a rather cheap valuation: NURS is cheaper than 100.00% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.42. NURS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 239
Fwd PE 7.89
NURS.CA Price Earnings VS Forward Price EarningsNURS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NURS is valued a bit cheaper than 80.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 185.05
NURS.CA Per share dataNURS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NURS's earnings are expected to grow with 267.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.61
PEG (5Y)N/A
EPS Next 2Y457.98%
EPS Next 3Y267.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NURS.CA Dividend Analysis

5.1 Amount

  • No dividends for NURS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NURS.CA Fundamentals: All Metrics, Ratios and Statistics

HYDREIGHT TECHNOLOGIES INC

TSX-V:NURS (3/20/2026, 7:00:00 PM)

2.39

-0.28 (-10.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-26
Earnings (Next)04-29
Inst Owners1.15%
Inst Owner ChangeN/A
Ins Owners1.89%
Ins Owner ChangeN/A
Market Cap127.60M
Revenue(TTM)24.48M
Net Income(TTM)453.30K
Analysts80
Price Target9.95 (316.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-12.44%
Min Revenue beat(2)-33.59%
Max Revenue beat(2)8.7%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.41%
PT rev (3m)27.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-25%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-23.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23.04%
Valuation
Industry RankSector Rank
PE 239
Fwd PE 7.89
P/S 5.21
P/FCF N/A
P/OCF 175.37
P/B 13.47
P/tB 17.8
EV/EBITDA 185.05
EPS(TTM)0.01
EY0.42%
EPS(NY)0.3
Fwd EY12.68%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.01
OCFY0.57%
SpS0.46
BVpS0.18
TBVpS0.13
PEG (NY)0.61
PEG (5Y)N/A
Graham Number0.2
Profitability
Industry RankSector Rank
ROA 2.04%
ROE 4.79%
ROCE 2.03%
ROIC 1.46%
ROICexc N/A
ROICexgc N/A
OM 1.48%
PM (TTM) 1.85%
GM 29.16%
FCFM N/A
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
F-Score5
Asset Turnover1.1
Health
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF N/A
Debt/EBITDA 12.5
Cap/Depr 535.2%
Cap/Sales 5.89%
Interest Coverage 250
Cash Conversion 115.22%
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z 7.47
F-Score5
WACC8.61%
ROIC/WACC0.17
Cap/Depr(3y)341%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)128.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%426.09%
EPS Next Y391.35%
EPS Next 2Y457.98%
EPS Next 3Y267.39%
EPS Next 5YN/A
Revenue 1Y (TTM)59.17%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%132.42%
Revenue Next Year125.3%
Revenue Next 2Y207.15%
Revenue Next 3Y130.32%
Revenue Next 5YN/A
EBIT growth 1Y124.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year570.31%
EBIT Next 3Y334.94%
EBIT Next 5YN/A
FCF growth 1Y46.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y313.05%
OCF growth 3YN/A
OCF growth 5YN/A

HYDREIGHT TECHNOLOGIES INC / NURS.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HYDREIGHT TECHNOLOGIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to NURS.CA.


What is the valuation status of HYDREIGHT TECHNOLOGIES INC (NURS.CA) stock?

ChartMill assigns a valuation rating of 6 / 10 to HYDREIGHT TECHNOLOGIES INC (NURS.CA). This can be considered as Fairly Valued.


How profitable is HYDREIGHT TECHNOLOGIES INC (NURS.CA) stock?

HYDREIGHT TECHNOLOGIES INC (NURS.CA) has a profitability rating of 5 / 10.


How financially healthy is HYDREIGHT TECHNOLOGIES INC?

The financial health rating of HYDREIGHT TECHNOLOGIES INC (NURS.CA) is 5 / 10.